Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population

World Journal of Gastroenterology

Volumn 15, Issue 44, 2009, Pages 5592-5597

  Leu, Jyh Der ^a   Lin, I Feng ^b   Sun, Ying Fang ^b   Chen, Su Mei ^a   Liu, Chih Chao ^b   Lee, Yi Jang ^b  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Hepatocellular carcinoma; MDM2 protein; Taiwan; Tumor suppressor protein p53

Indexed keywords

PROTEIN MDM2;

ADULT; AGED; ARTICLE; CANCER RISK; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENETIC RISK; GENOTYPE; HEPATITIS B; HEPATITIS C; HOMOZYGOSITY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN;

EID: 74049144962     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.5592     Document Type: Article

References (41)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16
2. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009; 24: 346-353
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
4. Luo RH, Zhao ZX, Zhou XY, Gao ZL, Yao JL. Risk factors for primary liver carcinoma in Chinese population. World J Gastroenterol 2005; 11: 4431-4434
5. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001; 120: 1763-1773
6. Kato N, Ji G, Wang Y, Baba M, Hoshida Y, Otsuka M, Taniguchi H, Moriyama M, Dharel N, Goto T, Shao RX, Matsuura T, Ishii K, Shiina S, Kawabe T, Muramatsu M, Omata M. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology 2005; 42: 846-853
7. Chen GG, Ho RL, Wong J, Lee KF, Lai PB. Single nucleotide polymorphism in the promoter region of human alphafetoprotein (AFP) gene and its significance in hepatocellular carcinoma (HCC). Eur J Surg Oncol 2007; 33: 882-886
8. Ezzikouri S, El Feydi AE, Benazzouz M, Afifi R, El Kihal L, Hassar M, Akil A, Pineau P, Benjelloun S. Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population. Infect Genet Evol 2009; 9: 877-881
9. Wu Y, Lin JS. DNA methyltransferase 3B promoter polymorphism and its susceptibility to primary hepatocellular carcinoma in the Chinese Han nationality population: a case-control study. World J Gastroenterol 2007; 13: 6082-6086
10. Zhu X, Chen MS, Tian LW, Li DP, Xu PL, Lin MC, Xie D, Kung HF. Single nucleotide polymorphism of rs430397 in the fifth intron of GRP78 gene and clinical relevance of primary hepatocellular carcinoma in Han Chinese: risk and prognosis. Int J Cancer 2009; 125: 1352-1357
11. Jeng JE, Tsai JF, Chuang LY, Ho MS, Lin ZY, Hsieh MY, Chen SC, Chuang WL, Wang LY, Yu ML, Dai CY, Chang JG. Heat shock protein A1B 1267 polymorphism is highly associated with risk and prognosis of hepatocellular carcinoma: a casecontrol study. Medicine (Baltimore) 2008; 87: 87-98
12. Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol 2005; 11: 289-292
13. Jin S, Levine AJ. The p53 functional circuit. J Cell Sci 2001; 114: 4139-4140
14. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003; 13: 49-58
15. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 1998; 95: 15608-15612
16. Endo K, Ueda T, Ohta T, Terada T. Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver 2000; 20: 209-215
17. Schoniger-Hekele M, Hanel S, Wrba F, Muller C. Hepatocellular carcinoma--survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liver Int 2005; 25: 62-69
18. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602
19. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 2007; 26: 1317-1323
20. Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, Omata M. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 2006; 12: 4867-4871
21. Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, Park JY, Myoung SM, Kim do Y, Chon CY, Han KH. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008; 29: 1192-1196
22. Ezzikouri S, El Feydi AE, Afifi R, El Kihal L, Benazzouz M, Hassar M, Marchio A, Pineau P, Benjelloun S. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Cancer Detect Prev 2009; 32: 380-385
23. Walsh CS, Miller CW, Karlan BY, Koeffler HP. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 2007; 104: 660-664
24. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273-278
25. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26: 153-161
26. Nissen NN, Martin P. Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol 2002; 35: S79-S85
27. Hu Z, Ma H, Lu D, Qian J, Zhou J, Chen Y, Xu L, Wang X, Wei Q, Shen H. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer 2006; 118: 1275-1278
28. Li G, Zhai X, Zhang Z, Chamberlain RM, Spitz MR, Wei Q. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 2006; 27: 2028-2033
29. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 2006; 119: 718-721
30. Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, Jin G, Liu J, Wang X, Wei Q, Shen H. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 2006; 240: 261-267
31. Millikan RC, Heard K, Winkel S, Hill EJ, Heard K, Massa B, Mayes L, Williams P, Holston R, Conway K, Edmiston S, de Cotret AR. No association between the MDM2 -309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol Biomarkers Prev 2006; 15: 175-177
32. Petenkaya A, Bozkurt B, Akilli-Ozturk O, Kaya HS, Gur-Dedeoglu B, Yulug IG. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res 2006; 26: 4975-4977
33. Pine, Mechanic LE, Bowman ED, Welsh JA, Chanock SC, Shields PG, Harris CC. MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 1559-1561
34. Sun YF, Leu JD, Chen SM, Lin IF, Lee YJ. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer. BMC Cancer 2009; 9: 13
35. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int J Cancer 2007; 120: 563-565
36. Wilkening S, Hemminki K, Rudnai P, Gurzau E, Koppova K, Forsti A, Kumar R. No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin. Br J Dermatol 2007; 157: 375-377
37. Economopoulos KP, Sergentanis TN. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat 2009; Epub ahead of print
38. Lu SN, Su WW, Yang SS, Chang TT, Cheng KS, Wu JC, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Chen CH. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 2006; 119: 1946-1952
39. Amarapurkar DN, Patel ND, Kamani PM. Impact of diabetes mellitus on outcome of HCC. Ann Hepatol 2008; 7: 148-151
40. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-380
41. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111-121